BLRX

BioLine RX Ltd (BLRX) | Rumor.io

BioLine RX

BLRX

Attention (50-day avg)0%

Attention rank (50-day avg)#1,227

Bullish sentiment (50-day avg)100%

Price to earnings ratio0

Market capitalization10.6M

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)1.2M

Net income (annual)-2M

Social

What share of all stock conversation is about BLRX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% new	0% 0	0% 0

Aug 31

BioLineRx Ltd.'s (BLRX) second-quarter 2026 revenue remained flat at $0.3 million, primarily driven by royalties from Aphexda sales.
The company's GLIX1 clinical trial is ongoing, with the second cohort dosing and the third expected to commence in September.
BioLineRx has $13.1 million in cash, providing a runway into the first half of 2027, and has accepted GLIX1 clinical and pre-clinical data for publication at upcoming conferences.

Generated by AI

Sentiment

Of the messages about BLRX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100%	69% +10.29
Bearish	—	—	0%	31% -10.29

Bullish· Jun 6

$BLRX has a nano float, zero shares to borrow, and nearly 600% borrow fee, indicating big move potential.
A squeeze in $BLRX could trigger a supernova, with the asset breaking through the $10 level and triggering a significant price increase.
$BLRX has a healthy pullback, and a close above $6.23 in the power hour could be a bullish sign, potentially leading to a breakout and a big move in the coming weeks.

Bearish· May 30

$BLRX has been experiencing a series of rapid price declines, with the stock falling after each of the author's trades.
The company is at risk of dilution and may not have sufficient liquidity to sustain its current stock price.
The author believes the company is not viable in the long term and is likely to become bankrupt, with the current price being the result of a final pump before the inevitable decline.

Generated by AI

Topics

Of the messages about BLRX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	41.67%	86.75%	91.3%
Technical Analysis	—	58.33%	4.64%	2.81%
Analysts	—	0%	5.3%	2.05%
Earnings	—	0%	3.31%	2.56%
Controversies	—	0%	0%	1.28%
Macro	—	0%	0%	0%

Analysts· Jun 22

BioLineRx Ltd. has been initiated or reaffirmed by several analysts, including Roth Capital and JMP Securities, with Buy or Outperform ratings.
Roth Capital has a price target of $10.50 for BioLineRx, while JMP Securities has a price target of $5.00.
Analysts have expressed optimism about BioLineRx, with JMP Securities starting coverage at Market Outperform and Roth Capital affirming its Buy rating.

Announcements· May 30

BioLineRx Ltd. ($BLRX) announced new pilot phase data from its Phase 2 combination trial of motixafortide in first-line pancreatic cancer (PDAC) to be presented at ASCO 2025 Annual Meeting.
The pilot study demonstrated a higher overall response rate (64%) and disease control rate (91%) in patients receiving the combination therapy.
Updated results from the pilot phase indicate that four of eleven patients remained progression-free after more than one year, with two patients achieving complete or sustained partial responses.

Technical Analysis· May 30

BioLineRx Ltd. ($BLRX) has a potential breakout at $10.50, but needs to clear this level for a next push up.
The stock is forming a bullish descending wedge and has a possible cup and handle pattern, with a potential bounce up before a drop again near $5.25.
The 200 moving average is acting as a ceiling above the stock, and a close above $5.50 levels on the 15-minute chart could create another move up.

Generated by AI

Community

Of the messages about BLRX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	100%	41.36%	65.12%
Newcomers	—	0%	58.64%	34.88%

Regulars· May 30

The pilot phase of BioLineRx's CheMo4METPANC Phase 2 trial for first-line pancreatic cancer demonstrated a higher overall response rate (64%) and disease control rate (91%).
A poster presenting new data from the trial will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.
BioLineRx's stock (BLRX) is being closely watched by investors due to its low float and recent price movement, with some expecting a potential price increase.

Newcomers· Aug 31

The company's Q2 results missed estimates, with revenue coming in at $294K vs. $500K expected, but the stock is rising due to progress with GLIX1.
A 424B5 filing was submitted, outlining a registered direct offering of 480,696 ADSs and 868,225 pre-funded warrants, which will raise $3.75M and dilute the company's market cap by 31%.
The stock's historical earnings-day performance has been negative, with 100% of past earnings days closing lower and an average move of -3.51%.

Generated by AI

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, and Hemispherian AS, a clinical-stage oncology company developing novel small molecule therapeutics, today announced that two abstracts featuring GLIX1 have been accepted for presentation, including one selected for oral presentation highlighting the preclinical efficacy of GLIX1 in orthotopic glioblastoma models, at the 21st Meeting of the Europe

20d agoYahoo Finance

BioLineRx and Hemispherian AS to Present Encouraging GLIX1 Preclinical Efficacy Data and its Phase 1/2a Trial Design at the 21st Meeting of the European Association of Neuro-Oncology (EANO 2026) – Company Announcement - FT.com

20d agoFinancial Times

Exclusive BAC Article: BioLineRx; Futility Analysis Motixafortide PDAC 2026, GLIX1 Phase 1/2 Data 2026/2027, Potential PARP Collaboration, And Catalysts (NASDAQ:BLRX)

I believe that a good speculative biotech to go over for the Exclusive BAC Subscribers Article would be BioLineRx (BLRX).

27d agoSeeking Alpha

BLRX: New GLIX1 Data Touts Synergies

By John Vandermosten, CFA NASDAQ: BLRX READ THE FULL BLRX RESEARCH REPORT BioLineRx Ltd. (NASDAQ: BLRX) reported second quarter 2026 financial and operational results in an August 31 st press release. For the quarter, it produced license revenues of $294,000 and a net loss of $4.3 million. The joint venture (JV) with Hemispherian, which is developing GLIX1, has begun enrolling the second of five

29d agoYahoo Finance

Earnings call transcript: BioLineRx Q2 2026 revenue flat as GLIX1 advances

29d agoInvesting.com

Also Discussed

Investors talking about BLRX also mention

#	Name	Attention
1	Can-Fite BioPharma Ltd. ADRCANF	0%0
2	Verastem Inc.VSTM	0%0
3	BLPH - Bellerophon Therapeutics, Inc.	——
4	Catalyst Pharmaceuticals Inc.CPRX	0%new
5	Protalix BioTherapeutics, Inc.PLX	0%+0
6	Kamada Ltd.KMDA	0%0
7	BCLI - Brainstorm Cell Therapeutics Inc.	——
8	Palvella Therapeutics IncPIRS	0%0
9	SCYNEXIS, Inc. Common StockSCYX	0%-0.02
10	Precipio Inc.PRPO	0%0

BioLine RX Ltd

Healthcare
Biotechnology

BioLineRx Ltd. Sponsored ADR is a biopharmaceutical company focused on developing and commercializing therapies for oncology and other serious diseases. BioLineRx Ltd. pursues a portfolio centered on cancer treatment, including clinical-stage and marketed assets that address areas such as stem cell mobilization, solid tumors, and rare disease-related needs. The company works through research, development, and partnership-based programs that advance small-molecule and peptide-based candidates across clinical stages. Its current activity also includes therapies designed for immuno-oncology, DNA damage response, and supportive care applications, along with legacy products in dermatology. BioLineRx Ltd. plays a niche role in the healthcare market by concentrating on specialized therapeutic candidates that target unmet medical needs and by collaborating with external partners to support development and commercialization efforts.

Website

Location

Modi’in Technology Park

Hevel Modi'in, 7177871

Israel

Social

What share of all stock conversation is about BLRX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% new	0% 0	0% 0

Aug 31

BioLineRx Ltd.'s (BLRX) second-quarter 2026 revenue remained flat at $0.3 million, primarily driven by royalties from Aphexda sales.
The company's GLIX1 clinical trial is ongoing, with the second cohort dosing and the third expected to commence in September.
BioLineRx has $13.1 million in cash, providing a runway into the first half of 2027, and has accepted GLIX1 clinical and pre-clinical data for publication at upcoming conferences.

Generated by AI

Sentiment

Of the messages about BLRX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100%	69% +10.29
Bearish	—	—	0%	31% -10.29

Bullish· Jun 6

$BLRX has a nano float, zero shares to borrow, and nearly 600% borrow fee, indicating big move potential.
A squeeze in $BLRX could trigger a supernova, with the asset breaking through the $10 level and triggering a significant price increase.
$BLRX has a healthy pullback, and a close above $6.23 in the power hour could be a bullish sign, potentially leading to a breakout and a big move in the coming weeks.

Bearish· May 30

$BLRX has been experiencing a series of rapid price declines, with the stock falling after each of the author's trades.
The company is at risk of dilution and may not have sufficient liquidity to sustain its current stock price.
The author believes the company is not viable in the long term and is likely to become bankrupt, with the current price being the result of a final pump before the inevitable decline.

Generated by AI

Topics

Of the messages about BLRX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	41.67%	86.75%	91.3%
Technical Analysis	—	58.33%	4.64%	2.81%
Analysts	—	0%	5.3%	2.05%
Earnings	—	0%	3.31%	2.56%
Controversies	—	0%	0%	1.28%
Macro	—	0%	0%	0%

Analysts· Jun 22

BioLineRx Ltd. has been initiated or reaffirmed by several analysts, including Roth Capital and JMP Securities, with Buy or Outperform ratings.
Roth Capital has a price target of $10.50 for BioLineRx, while JMP Securities has a price target of $5.00.
Analysts have expressed optimism about BioLineRx, with JMP Securities starting coverage at Market Outperform and Roth Capital affirming its Buy rating.

Announcements· May 30

BioLineRx Ltd. ($BLRX) announced new pilot phase data from its Phase 2 combination trial of motixafortide in first-line pancreatic cancer (PDAC) to be presented at ASCO 2025 Annual Meeting.
The pilot study demonstrated a higher overall response rate (64%) and disease control rate (91%) in patients receiving the combination therapy.
Updated results from the pilot phase indicate that four of eleven patients remained progression-free after more than one year, with two patients achieving complete or sustained partial responses.

Technical Analysis· May 30

BioLineRx Ltd. ($BLRX) has a potential breakout at $10.50, but needs to clear this level for a next push up.
The stock is forming a bullish descending wedge and has a possible cup and handle pattern, with a potential bounce up before a drop again near $5.25.
The 200 moving average is acting as a ceiling above the stock, and a close above $5.50 levels on the 15-minute chart could create another move up.

Generated by AI

Community

Of the messages about BLRX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	100%	41.36%	65.12%
Newcomers	—	0%	58.64%	34.88%

Regulars· May 30

The pilot phase of BioLineRx's CheMo4METPANC Phase 2 trial for first-line pancreatic cancer demonstrated a higher overall response rate (64%) and disease control rate (91%).
A poster presenting new data from the trial will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.
BioLineRx's stock (BLRX) is being closely watched by investors due to its low float and recent price movement, with some expecting a potential price increase.

Newcomers· Aug 31

The company's Q2 results missed estimates, with revenue coming in at $294K vs. $500K expected, but the stock is rising due to progress with GLIX1.
A 424B5 filing was submitted, outlining a registered direct offering of 480,696 ADSs and 868,225 pre-funded warrants, which will raise $3.75M and dilute the company's market cap by 31%.
The stock's historical earnings-day performance has been negative, with 100% of past earnings days closing lower and an average move of -3.51%.

Generated by AI

BioLine RX

Social

Aug 31

Bullish· Jun 6

Bearish· May 30

Analysts· Jun 22

Announcements· May 30

Technical Analysis· May 30

Regulars· May 30

Newcomers· Aug 31

BioLineRx, Hemispherian to present GLIX1 data at EANO meeting

BioLineRx and Hemispherian AS to Present Encouraging GLIX1 Preclinical Efficacy Data and its Phase 1/2a Trial Design at the 21st Meeting of the European Association of Neuro-Oncology (EANO 2026)

BioLineRx and Hemispherian AS to Present Encouraging GLIX1 Preclinical Efficacy Data and its Phase 1/2a Trial Design at the 21st Meeting of the European Association of Neuro-Oncology (EANO 2026) – Company Announcement - FT.com

Exclusive BAC Article: BioLineRx; Futility Analysis Motixafortide PDAC 2026, GLIX1 Phase 1/2 Data 2026/2027, Potential PARP Collaboration, And Catalysts (NASDAQ:BLRX)

BLRX: New GLIX1 Data Touts Synergies

Earnings call transcript: BioLineRx Q2 2026 revenue flat as GLIX1 advances

Also Discussed

BioLine RX Ltd

Company Information

Location

BioLineRx, Hemispherian to present GLIX1 data at EANO meeting

BioLineRx and Hemispherian AS to Present Encouraging GLIX1 Preclinical Efficacy Data and its Phase 1/2a Trial Design at the 21st Meeting of the European Association of Neuro-Oncology (EANO 2026)

BioLineRx and Hemispherian AS to Present Encouraging GLIX1 Preclinical Efficacy Data and its Phase 1/2a Trial Design at the 21st Meeting of the European Association of Neuro-Oncology (EANO 2026) – Company Announcement - FT.com

Exclusive BAC Article: BioLineRx; Futility Analysis Motixafortide PDAC 2026, GLIX1 Phase 1/2 Data 2026/2027, Potential PARP Collaboration, And Catalysts (NASDAQ:BLRX)

BLRX: New GLIX1 Data Touts Synergies

Earnings call transcript: BioLineRx Q2 2026 revenue flat as GLIX1 advances

Also Discussed

Social

Aug 31

Bullish· Jun 6

Bearish· May 30

Analysts· Jun 22

Announcements· May 30

Technical Analysis· May 30

Regulars· May 30

Newcomers· Aug 31